Gilead Sciences stock gains as licensing deal and dividend support outlook

Published on 09/18/2026 at 13:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock closed at USD 150.89 on September 17, 2026, up 22.9 percent year to date and offering a 2.2 percent dividend yield. The latest quarter brought USD 7.8 billion in revenue, 10.2 percent above the prior year, with EPS at USD -6.75.

Photorealistischer Biotech-Campus von Gilead Sciences mit Glaslabor und Wissenschaftlern — Gilead Sciences Forschungscampus mit ISIN US3755581036 modernes Biopharma-Labor Kalifornien Glasfassade Wissenschaftler arbeiten, Illustration mit AI erstellt.

Gilead Sciences, Inc. stock (ISIN US3755581036) closed at USD 150.89 on Nasdaq on September 17, 2026, 22.9 percent above its level at the start of the year and offering investors a 2.2 percent dividend yield from a quarterly dividend of USD 0.82 per share.

Dividend and recent earnings underpin Gilead

According to MarketBeat, Gilead Sciences stock was trading at USD 122.74 at the start of 2026 and has since risen to USD 150.89, an increase of 22.9 percent as of September 17, 2026.

As MarketBeat reports, Gilead pays a quarterly dividend of USD 0.82 per share with a scheduled payment date of September 29, 2026 to shareholders of record on September 15, 2026, corresponding to an annualized dividend of USD 3.28 and a yield of 2.2 percent at the current share price.

Latest quarter shows double-digit revenue growth

Gilead’s latest reported quarter delivered a clear growth signal in the top line. According to Yahoo Finance, the company generated revenue of USD 7.8 billion in its most recently reported quarter, representing a 10.2 percent increase compared with the same quarter a year earlier.

In the same quarter, Gilead posted earnings per share of USD -6.75, down from USD 2.01 a year ago, reflecting the impact of one-off items; this EPS outcome still surprised positively versus the consensus estimate, beating expectations by 4.53 percent as highlighted by Yahoo Finance.

Analyst consensus and valuation context

Analysts remain constructive on the pharmaceutical group. Based on data summarized by MarketBeat on September 18, 2026, Gilead Sciences has a consensus rating of Moderate Buy and an average analyst price target of USD 158.78, implying upside potential of around 5 percent from the latest close of USD 150.89.

The same overview from MarketBeat notes that institutional investors such as Nykredit A S have recently increased their exposure to Gilead, with a disclosed investment of USD 140.59 million, adding to the impression that the stock’s defensive cash flow profile and dividend are attracting long-term capital.

Clinical and partnership backdrop adds longer-term angle

The fundamental picture around HIV prevention and treatment is also a key part of the equity story, even though it does not move the share price every day. Commentary on Gilead’s HIV franchise from Simply Wall St highlights analyst projections for revenues of USD 34.5 billion and earnings of USD 10.8 billion by 2029, based on an assumed annual revenue growth rate of 5.1 percent from around USD 9.2 billion of earnings today; these longer-term estimates frame the current share price against expected progress in HIV access and new long-acting regimens.

Sector news also points to Gilead’s role in broader partnerships: a licensing deal for once-yearly lenacapavir to prevent HIV, agreed with Dr. Reddy’s Laboratories, has been cited as part of a bullish narrative for both companies in an article from Sahi dated September 18, 2026, underscoring how Gilead’s pipeline assets are being leveraged through global partnerships.

Stock level and market metrics

Per data from MarketBeat, Gilead Sciences stock closed at USD 150.89 on Nasdaq on September 17, 2026, after gaining 3.21 points or 2.17 percent during that trading session, with the shares trading within a 52-week band that places the current level close to the upper end of the range.

The same price overview from MarketBeat indicates that Gilead’s year-to-date performance stands at plus 22.9 percent compared with its price of USD 122.74 at the start of 2026, a development that positions the stock ahead of many defensive healthcare names in terms of capital gains while still distributing cash via dividends.

Closing price context for investors

For retail investors evaluating Gilead Sciences stock today, the combination of a closing price of USD 150.89 on Nasdaq as of September 17, 2026, a 22.9 percent year-to-date gain and an annualized dividend yield of 2.2 percent is supported by recent quarterly revenue growth of 10.2 percent and a Moderate Buy analyst consensus with an average price target of USD 158.78.